Pirozzi Angelo, Riccardi Ferdinando, Arpino Grazia, Mocerino Carmela, Campione Severo, Molino Carlo, Cartenì Giacomo
Department of Clinical Medicine and Surgery, University of Naples Federico II.
Department of Medical Oncology, Azienda Ospedaliero-Universitaria.
Medicine (Baltimore). 2019 Jul;98(29):e16508. doi: 10.1097/MD.0000000000016508.
There is an association between the presence of neuroendocrine neoplasms and incremented risk to develop second primary malignancies. This risk is estimated to be 17%. The most common secondary neoplasms were found in the Gastrointestinal and Genitourinary tracts.
A 74-year-old Caucasian patient with melaena came to our observation in June 2015. The Esophago-gastro-duodenoscopy exam found a polypoid formation in the duodenal bulb. Histopathological examination showed a well-differentiated neuroendocrine neoplasm (G1).
During the follow up for the neuroendocrine neoplasm, a CT scan was performed in August 2016 describing infiltration of the right renal sinus and the third proximal ureter segment with heterogeneous enhancement of vascular structure. An US-guided biopsy was conclusive for a Diffuse Large B Cell Lymphoma. In October 2016, a colonoscopy showed a neoplastic lesion at 20 cm from the anal orifice. The Histology exam was positive for an adenocarcinoma with a desmoplastic stroma infiltration.
In November 2016, the patient underwent a left hemicolectomy: the pathologic staging described a G2 adenocarcinoma pT3N1b. In May 2018, the Octreotide scan was negative. In the same month, the patient started a treatment based on 6 cycles of Rituximab, Oxaliplatin, and Capecitabine due to the persistence of lymphomatous disease and hepatic metastases. In July 2018, other 3 cycles of the same treatment were scheduled.
In January 2019, due to an increase in liver metastases' size, it was decided to start a new regimen for the colon cancer with FOLFIRI+Cetuximab. The patient is still in treatment with this regimen in April 2019.
The risk of a second primary tumor is increased among patients older than 70. Therefore, it is necessary to follow them using total body CT scan and endoscopic techniques of gastrointestinal and genitourinary tracts, not only for the evaluation of the neuroendocrine tumor but also for the higher risk to develop other neoplastic diseases.
神经内分泌肿瘤的存在与发生第二原发性恶性肿瘤的风险增加之间存在关联。这种风险估计为17%。最常见的继发性肿瘤见于胃肠道和泌尿生殖道。
一名74岁的白种人患者因黑便于2015年6月前来我院就诊。食管胃十二指肠镜检查发现十二指肠球部有息肉样肿物。组织病理学检查显示为高分化神经内分泌肿瘤(G1)。
在对神经内分泌肿瘤的随访期间,2016年8月进行了CT扫描,结果显示右肾窦和近端输尿管第三段有浸润,血管结构强化不均匀。超声引导下活检确诊为弥漫性大B细胞淋巴瘤。2016年10月,结肠镜检查显示距肛门孔20厘米处有一个肿瘤性病变。组织学检查显示为腺癌伴促纤维增生性基质浸润阳性。
2016年11月,患者接受了左半结肠切除术:病理分期为G2腺癌pT3N1b。2018年5月,奥曲肽扫描结果为阴性。同月,由于淋巴瘤疾病持续存在且有肝转移,患者开始接受基于6个周期的利妥昔单抗、奥沙利铂和卡培他滨的治疗。2018年7月,计划再进行3个周期的相同治疗。
2019年1月,由于肝转移灶增大,决定开始使用FOLFIRI+西妥昔单抗治疗结肠癌的新方案。2019年4月,患者仍在接受该方案治疗。
70岁以上患者发生第二原发性肿瘤的风险增加。因此,有必要对他们进行全身CT扫描以及胃肠道和泌尿生殖道的内镜检查,不仅用于评估神经内分泌肿瘤,也用于评估发生其他肿瘤性疾病的较高风险。